Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

por Miyauchi, Akimitsu, Dinavahi, Rajani V., Crittenden, Daria B., Yang, Wenjing, Maddox, Judy C., Hamaya, Etsuro, Nakamura, Yoichi, Libanati, Cesar, Grauer, Andreas, Shimauchi, Junichiro
Publicado 2019

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

por Geusens, Piet, Oates, Mary, Miyauchi, Akimitsu, Adachi, Jonathan D, Lazaretti‐Castro, Marise, Ebeling, Peter R, Perez Niño, Carlos Augusto, Milmont, Cassandra E, Grauer, Andreas, Libanati, Cesar
Publicado 2019

Romosozumab and antiresorptive treatment: the importance of treatment sequence

por Cosman, Felicia, Kendler, David L., Langdahl, Bente L., Leder, Benjamin Z., Lewiecki, E. Michael, Miyauchi, Akimitsu, Rojeski, Maria, McDermott, Michele, Oates, Mary K., Milmont, Cassandra E., Libanati, Cesar, Ferrari, Serge
Publicado 2022

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease

por Miller, Paul D, Adachi, Jonathan D, Albergaria, Ben‐Hur, Cheung, Angela M, Chines, Arkadi A, Gielen, Evelien, Langdahl, Bente L, Miyauchi, Akimitsu, Oates, Mary, Reid, Ian R, Santiago, Norma Ruiz, Vanderkelen, Mark, Wang, Zhenxun, Yu, Zhigang
Publicado 2022